Publications
Print PDF
In Pfizer-Seagen Review, FTC has Chance to Set New Pharma Precedent
March 14, 2023
Jonathan Gardner
BioPharma Dive

Axinn partner Jeny Maier was quoted in the BioPharma Dive article, "In Pfizer-Seagen Review, FTC has Chance to Set New Pharma Precedent."

Click here to access the article. 

By using the Axinn, Veltrop & Harkrider LLP website with cookies enabled on your browser, you agree to our use of cookies during your browsing experience. Learn more about our privacy policy.